Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine plus PD-1/PD-L1 inhibitor maintenance after first-line platinum chemotherapy for advanced lung squamous cell carcinoma
ChiCTR2200057029Phase 2Not yet recruiting
- Sponsor
- The Seventh Affiliated Hospital, Sun Yat-Sen University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine in Pulmonary squamous cell carcinoma, sponsored by The Seventh Affiliated Hospital, Sun Yat-Sen University. Primary endpoint: Progression-free survival. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
vinorelbine
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2200057029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057029.